Too much ara-C? Not enough daunorubicin?

It seems strange, but after 40 years of experience using cytosine arabinoside (ara-C) and daunorubicin, leukemia doctors are still unsure as to how much of each drug they should use to treat their patients with acute myeloid leukemia (AML).

Saved in:
Bibliographic Details
Published in:Blood 2011-02, Vol.117 (8), p.2299-2300
Main Author: Feldman, Eric J.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c407t-e91cfd864d491195ae20aea364d10379ca8a7051adc9cba17389de1d18bd24ab3
cites cdi_FETCH-LOGICAL-c407t-e91cfd864d491195ae20aea364d10379ca8a7051adc9cba17389de1d18bd24ab3
container_end_page 2300
container_issue 8
container_start_page 2299
container_title Blood
container_volume 117
creator Feldman, Eric J.
description It seems strange, but after 40 years of experience using cytosine arabinoside (ara-C) and daunorubicin, leukemia doctors are still unsure as to how much of each drug they should use to treat their patients with acute myeloid leukemia (AML).
doi_str_mv 10.1182/blood-2011-01-328633
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_853995208</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120569590</els_id><sourcerecordid>853995208</sourcerecordid><originalsourceid>FETCH-LOGICAL-c407t-e91cfd864d491195ae20aea364d10379ca8a7051adc9cba17389de1d18bd24ab3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gcje9BKdSXa7yUWR4hcUvdRzyCapjWw3NdkV_Pdu3erR08DwvPMyDyGnCJeIgl1VdQiWMkCkgJQzMeV8j4yxYIICMNgnYwCY0lyWOCJHKb0DYM5ZcUhGDHkBUIgxuViEkK07s8p01HR2kz2HNnNN6N5WmdVdE2JXeeObm2NysNR1cie7OSGv93eL2SOdvzw8zW7n1ORQttRJNEsrprnNJaIstGOgneb9AoGX0mihSyhQWyNNpbHkQlqHFkVlWa4rPiHnw91NDB-dS61a-2RcXevGhS4pUXApCwaiJ_OBNDGkFN1SbaJf6_ilENRWkfpRpLaKFKAaFPWxs11BV62d_Qv9OumB6wFw_Zuf3kWVjHeNcdZHZ1plg_-_4RuNqHX5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>853995208</pqid></control><display><type>article</type><title>Too much ara-C? Not enough daunorubicin?</title><source>Elsevier ScienceDirect Journals</source><creator>Feldman, Eric J.</creator><creatorcontrib>Feldman, Eric J.</creatorcontrib><description>It seems strange, but after 40 years of experience using cytosine arabinoside (ara-C) and daunorubicin, leukemia doctors are still unsure as to how much of each drug they should use to treat their patients with acute myeloid leukemia (AML).</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2011-01-328633</identifier><identifier>PMID: 21350058</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><ispartof>Blood, 2011-02, Vol.117 (8), p.2299-2300</ispartof><rights>2011 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c407t-e91cfd864d491195ae20aea364d10379ca8a7051adc9cba17389de1d18bd24ab3</citedby><cites>FETCH-LOGICAL-c407t-e91cfd864d491195ae20aea364d10379ca8a7051adc9cba17389de1d18bd24ab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120569590$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27901,27902,45756</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21350058$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Feldman, Eric J.</creatorcontrib><title>Too much ara-C? Not enough daunorubicin?</title><title>Blood</title><addtitle>Blood</addtitle><description>It seems strange, but after 40 years of experience using cytosine arabinoside (ara-C) and daunorubicin, leukemia doctors are still unsure as to how much of each drug they should use to treat their patients with acute myeloid leukemia (AML).</description><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlb_gcje9BKdSXa7yUWR4hcUvdRzyCapjWw3NdkV_Pdu3erR08DwvPMyDyGnCJeIgl1VdQiWMkCkgJQzMeV8j4yxYIICMNgnYwCY0lyWOCJHKb0DYM5ZcUhGDHkBUIgxuViEkK07s8p01HR2kz2HNnNN6N5WmdVdE2JXeeObm2NysNR1cie7OSGv93eL2SOdvzw8zW7n1ORQttRJNEsrprnNJaIstGOgneb9AoGX0mihSyhQWyNNpbHkQlqHFkVlWa4rPiHnw91NDB-dS61a-2RcXevGhS4pUXApCwaiJ_OBNDGkFN1SbaJf6_ilENRWkfpRpLaKFKAaFPWxs11BV62d_Qv9OumB6wFw_Zuf3kWVjHeNcdZHZ1plg_-_4RuNqHX5</recordid><startdate>20110224</startdate><enddate>20110224</enddate><creator>Feldman, Eric J.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110224</creationdate><title>Too much ara-C? Not enough daunorubicin?</title><author>Feldman, Eric J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c407t-e91cfd864d491195ae20aea364d10379ca8a7051adc9cba17389de1d18bd24ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feldman, Eric J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feldman, Eric J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Too much ara-C? Not enough daunorubicin?</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2011-02-24</date><risdate>2011</risdate><volume>117</volume><issue>8</issue><spage>2299</spage><epage>2300</epage><pages>2299-2300</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>It seems strange, but after 40 years of experience using cytosine arabinoside (ara-C) and daunorubicin, leukemia doctors are still unsure as to how much of each drug they should use to treat their patients with acute myeloid leukemia (AML).</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21350058</pmid><doi>10.1182/blood-2011-01-328633</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2011-02, Vol.117 (8), p.2299-2300
issn 0006-4971
1528-0020
language eng
recordid cdi_proquest_miscellaneous_853995208
source Elsevier ScienceDirect Journals
title Too much ara-C? Not enough daunorubicin?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T09%3A59%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Too%20much%20ara-C?%20Not%20enough%20daunorubicin?&rft.jtitle=Blood&rft.au=Feldman,%20Eric%20J.&rft.date=2011-02-24&rft.volume=117&rft.issue=8&rft.spage=2299&rft.epage=2300&rft.pages=2299-2300&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2011-01-328633&rft_dat=%3Cproquest_cross%3E853995208%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c407t-e91cfd864d491195ae20aea364d10379ca8a7051adc9cba17389de1d18bd24ab3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=853995208&rft_id=info:pmid/21350058&rfr_iscdi=true